Revumenib

**Semantic type:** Pharmacologic Substance

**Definition:** An orally bioavailable protein-protein interaction (PPI) inhibitor of the menin-mixed lineage leukemia (MLL; myeloid/lymphoid leukemia; KMT2A) proteins, with potential antineoplastic activity. Upon oral administration, revumenib targets and binds to the nuclear protein menin, thereby preventing the interaction between the two proteins menin and MLL and the formation of the menin-MLL complex. This reduces the expression of downstream target genes and results in an inhibition of the proliferation of MLL-rearranged leukemic cells. The menin-MLL complex plays a key role in the survival, growth, transformation and proliferation of certain kinds of leukemia cells.

**Synonyms:** - Benzamide, N-ethyl-2-((4-(7-((trans-4-((ethylsulfonyl)amino)cyclohexyl)methyl)-2,7-diazaspiro(3.5)non-2-yl)-5-pyrimidinyl)oxy)-5-fluoro-N-(1-methylethyl)- - Menin-MLL Inhibitor SNDX-5613 - Menin-MLL Interaction Inhibitor SNDX-5613 - Menin-Mixed Lineage Leukemia Protein-Protein Interaction Inhibitor SNDX-5613 - REVUMENIB - SNDX 5613 - SNDX-5613 - SNDX5613